CST3 and diabetic kidney disease: Plasma potential biomarkers such as apolipoprotein C-I, apoA-I, transthyretin, and cystatin C were purposed to predict the progression and response to the treatment in diabetic kidney disease (Riaz, 2015; Pena et al., 2016).